128 related articles for article (PubMed ID: 37395154)
1. Dementia risk in patients with type 2 diabetes: Comparing metformin with no pharmacological treatment.
Zheng B; Su B; Ahmadi-Abhari S; Kapogiannis D; Tzoulaki I; Riboli E; Middleton L
Alzheimers Dement; 2023 Dec; 19(12):5681-5689. PubMed ID: 37395154
[TBL] [Abstract][Full Text] [Related]
2. Metformin and primary bone cancer risk in Taiwanese patients with type 2 diabetes mellitus.
Tseng CH
Bone; 2021 Oct; 151():116037. PubMed ID: 34116220
[TBL] [Abstract][Full Text] [Related]
3. Incident dementia risk among patients with type 2 diabetes receiving metformin versus alternative oral glucose-lowering therapy: an observational cohort study using UK primary healthcare records.
Doran W; Tunnicliffe L; Muzambi R; Rentsch CT; Bhaskaran K; Smeeth L; Brayne C; Williams DM; Chaturvedi N; Eastwood SV; Dunachie SJ; Mathur R; Warren-Gash C
BMJ Open Diabetes Res Care; 2024 Jan; 12(1):. PubMed ID: 38272537
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneous treatment effects of metformin on risk of dementia in patients with type 2 diabetes: A longitudinal observational study.
Tang H; Guo J; Shaaban CE; Feng Z; Wu Y; Magoc T; Hu X; Donahoo WT; DeKosky ST; Bian J
Alzheimers Dement; 2024 Feb; 20(2):975-985. PubMed ID: 37830443
[TBL] [Abstract][Full Text] [Related]
5. Metformin is associated with a lower risk of non-Hodgkin lymphoma in patients with type 2 diabetes.
Tseng CH
Diabetes Metab; 2019 Oct; 45(5):458-464. PubMed ID: 31129317
[TBL] [Abstract][Full Text] [Related]
6. Metformin vs sulfonylurea use and risk of dementia in US veterans aged ≥65 years with diabetes.
Orkaby AR; Cho K; Cormack J; Gagnon DR; Driver JA
Neurology; 2017 Oct; 89(18):1877-1885. PubMed ID: 28954880
[TBL] [Abstract][Full Text] [Related]
7. Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus.
Kuan YC; Huang KW; Lin CL; Hu CJ; Kao CH
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):77-83. PubMed ID: 28583443
[TBL] [Abstract][Full Text] [Related]
8. Risk of incident dementia following metformin initiation compared with noninitiation or delay of antidiabetic medication therapy.
Salas J; Morley JE; Scherrer JF; Floyd JS; Farr SA; Zubatsky M; Barthold D; Dublin S
Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):623-634. PubMed ID: 32363681
[TBL] [Abstract][Full Text] [Related]
9. No association between metformin initiation and incident dementia in older adults newly diagnosed with diabetes.
Wu CY; Wang C; Saskin R; Shah BR; Kapral MK; Lanctôt KL; Herrmann N; Cogo-Moreira H; MacIntosh BJ; Edwards JD; Swardfager W
J Intern Med; 2024 Jan; 295(1):68-78. PubMed ID: 37747779
[TBL] [Abstract][Full Text] [Related]
10. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial.
Tsilidis KK; Capothanassi D; Allen NE; Rizos EC; Lopez DS; van Veldhoven K; Sacerdote C; Ashby D; Vineis P; Tzoulaki I; Ioannidis JP
Diabetes Care; 2014 Sep; 37(9):2522-32. PubMed ID: 24898303
[TBL] [Abstract][Full Text] [Related]
11. Impact of time to treatment intensification on glycemic goal attainment among patients with type 2 diabetes failing metformin monotherapy.
Rajpathak SN; Rajgopalan S; Engel SS
J Diabetes Complications; 2014; 28(6):831-5. PubMed ID: 25104238
[TBL] [Abstract][Full Text] [Related]
12. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin.
Hsu CC; Wahlqvist ML; Lee MS; Tsai HN
J Alzheimers Dis; 2011; 24(3):485-93. PubMed ID: 21297276
[TBL] [Abstract][Full Text] [Related]
13. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
[TBL] [Abstract][Full Text] [Related]
14. Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia.
Yu O; Azoulay L; Yin H; Filion KB; Suissa S
Am J Med; 2018 Mar; 131(3):317.e11-317.e22. PubMed ID: 29032229
[TBL] [Abstract][Full Text] [Related]
15. Trends in Timing of and Glycemia at Initiation of Second-line Type 2 Diabetes Treatment in U.S. Adults.
Raghavan S; Warsavage T; Liu WG; Raffle K; Josey K; Saxon DR; Phillips LS; Caplan L; Reusch JEB
Diabetes Care; 2022 Jun; 45(6):1335-1345. PubMed ID: 35344584
[TBL] [Abstract][Full Text] [Related]
16. Metformin versus sulphonylureas for new onset atrial fibrillation and stroke in type 2 diabetes mellitus: a population-based study.
Zhou J; Zhang G; Chang C; Chou OHI; Lee S; Leung KSK; Wong WT; Liu T; Wai AKC; Cheng SH; Zhang Q; Tse G
Acta Diabetol; 2022 May; 59(5):697-709. PubMed ID: 35112189
[TBL] [Abstract][Full Text] [Related]
17. Metformin in elderly type 2 diabetes mellitus: dose-dependent dementia risk reduction.
Sun M; Chen WM; Wu SY; Zhang J
Brain; 2024 Apr; 147(4):1474-1482. PubMed ID: 37878862
[TBL] [Abstract][Full Text] [Related]
18. Early Glycemic Control and Magnitude of HbA
Svensson E; Baggesen LM; Johnsen SP; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Thomsen RW
Diabetes Care; 2017 Jun; 40(6):800-807. PubMed ID: 28404659
[TBL] [Abstract][Full Text] [Related]
19. Metformin Use Is Associated With Slowed Cognitive Decline and Reduced Incident Dementia in Older Adults With Type 2 Diabetes: The Sydney Memory and Ageing Study.
Samaras K; Makkar S; Crawford JD; Kochan NA; Wen W; Draper B; Trollor JN; Brodaty H; Sachdev PS
Diabetes Care; 2020 Nov; 43(11):2691-2701. PubMed ID: 32967921
[TBL] [Abstract][Full Text] [Related]
20. Metformin use in elderly population with diabetes reduced the risk of dementia in a dose-dependent manner, based on the Korean NHIS-HEALS cohort.
Kim Y; Kim HS; Lee JW; Kim YS; You HS; Bae YJ; Lee HC; Han YE; Choi EA; Kim J; Kang HT
Diabetes Res Clin Pract; 2020 Dec; 170():108496. PubMed ID: 33068660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
